Insmed to present new Phase 3b ENCORE data on ARIKAYCE resistance in newly diagnosed MAC lung disease at IDWeek 2026
Insmed flagged new clinical data across TPIP, BRINSUPRI, ARIKAYCE for presentation at CHEST 2026 and IDWeek 2026. Results will be presented in the future, with late-breaking TPIP updates aimed at supporting longer-term use in PAH, PH-ILD. A new Phase 3 ASPEN post hoc analysis will link patient-reported sputum color to